Riboflavin, or vitamin B2, is a water-soluble B vitamin that plays a central role in cellular metabolism, mitochondrial function, and redox homeostasis. Biochemically, riboflavin is the precursor for the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), both of which are essential for the activity of a wide range of flavoproteins involved in oxidative metabolism. Riboflavin is absorbed in the proximal small intestine via a saturable carrier-mediated process and is rapidly converted intracellularly to FMN and subsequently to FAD, the latter being the predominant flavin coenzyme in tissues.
FMN and FAD serve as obligatory cofactors for enzymes involved in critical metabolic pathways, including the citric acid cycle, β-oxidation of fatty acids, and the electron transport chain. FAD is a key component of complex II (succinate dehydrogenase) in the mitochondrial respiratory chain, supporting ATP production via oxidative phosphorylation. Both FAD and FMN are redox-active molecules that facilitate electron transfer reactions by cycling between oxidized and reduced states. Additionally, riboflavin is required for the function of glutathione reductase, an FAD-dependent enzyme responsible for regenerating reduced glutathione (GSH) from oxidized glutathione (GSSG), making it a critical player in cellular antioxidant defense. Through these mechanisms, riboflavin contributes not only to energy production but also to the maintenance of redox balance, detoxification, and the integrity of the skin, mucosa, and visual system.
The recommended dietary allowance (RDA) for riboflavin is based on age, sex, and physiological status, including pregnancy and lactation. These values are established to meet the nutritional needs of nearly all healthy individuals in each age group. Infants under 12 months are provided with Adequate Intake (AI) levels due to insufficient data for establishing an RDA. The following table summarizes the current dietary reference intakes for riboflavin, as published by the National Institutes of Health (NIH, 2022).
| Age Group | RDA / AI for Riboflavin (mg/day) |
|---|---|
| Infants 0–6 months | 0.3 mg (AI) |
| Infants 7–12 months | 0.4 mg (AI) |
| Children 1–3 years | 0.5 mg |
| Children 4–8 years | 0.6 mg |
| Children 9–13 years | 0.9 mg |
| Males 14–18 years | 1.3 mg |
| Females 14–18 years | 1.0 mg |
| Males 19 years and older | 1.3 mg |
| Females 19 years and older | 1.1 mg |
| Pregnancy | 1.4 mg |
| Lactation | 1.6 mg |
Riboflavin is widely available in both animal and plant-based foods, though the highest concentrations are generally found in animal-derived products. In the modern diet, fortified cereals and grain products also contribute significantly to riboflavin intake, particularly in children. Riboflavin is a heat-stable vitamin but is highly sensitive to ultraviolet (UV) and visible light. Up to 75% of riboflavin content can be degraded when exposed to light for extended periods, particularly in transparent containers such as glass milk bottles. This photodegradation can significantly reduce dietary intake if light-sensitive foods like milk are not properly stored.
Many children may not meet optimal riboflavin intake if they follow restrictive or plant-based diets, avoid dairy, or consume primarily processed foods lacking fortification. Because riboflavin is water-soluble and not stored in large quantities in the body, consistent daily intake is important to prevent subclinical deficiencies.
Top dietary sources of riboflavin include:
Riboflavin deficiency, or ariboflavinosis, is relatively uncommon in developed countries due to widespread food fortification and the vitamin’s presence in a variety of animal and plant-based foods. However, subclinical deficiency and marginal riboflavin status may still occur in specific pediatric populations, especially in children with highly selective diets, malabsorptive disorders (e.g., celiac disease, inflammatory bowel disease), or chronic illness. Additional risk factors include hypothyroidism, anorexia nervosa, long-term use of phenobarbital or tricyclic antidepressants, and increased metabolic demand during growth, illness, or pregnancy.
Because riboflavin is integral to mitochondrial energy production and redox reactions, deficiency can impair both metabolic and antioxidant processes. Classic clinical signs are most prominent in tissues with high cell turnover, such as the skin and mucous membranes. Symptoms may include fatigue, glossitis (smooth, magenta tongue), angular stomatitis or cheilitis (cracking at the corners of the mouth), sore throat, and seborrheic dermatitis-like rashes, particularly around the nose and nasolabial folds. Ocular involvement such as photophobia, watering, and blurred vision may occur due to riboflavin’s role in maintaining corneal integrity. In children, prolonged deficiency may impair growth and neurodevelopment.
While overt deficiency is rare, marginal riboflavin status may contribute to functional B2 insufficiency, particularly in children with concurrent vitamin B6 or niacin deficiencies, since their metabolism is interdependent.
Common signs and symptoms of riboflavin deficiency:
Riboflavin is considered very safe for use in children, with no established Tolerable Upper Intake Level (UL) due to its low toxicity profile. As a water-soluble vitamin, excess riboflavin is readily excreted in the urine, often producing a bright yellow discoloration (flavinuria) that is benign and transient. The body tightly regulates intestinal absorption and renal reabsorption, making toxicity from food or standard supplementation exceedingly rare.
Clinical trials in both pediatric and adult populations—including those involving high-dose riboflavin for migraine prophylaxis and inborn errors of metabolism—have shown excellent safety and tolerability. Oral doses up to 400 mg/day in children have been used in clinical settings without significant adverse effects. Intravenous or injectable forms are rarely used in children except in hospital settings or metabolic emergencies and may carry a slightly higher risk of injection-site irritation or hypersensitivity, although reactions are still uncommon.
Despite its favorable safety profile, long-term use of isolated high-dose riboflavin may theoretically lead to imbalances in other B vitamins due to metabolic interdependence. For general supplementation in children—especially when dietary intake is uncertain or when supporting picky eaters—a balanced B-complex formulation is often preferred to ensure nutrient synergy.
Key safety considerations:
Riboflavin has been increasingly studied as a prophylactic treatment for migraines, including in pediatric populations, due to its critical role in mitochondrial energy metabolism. Migraines are believed to result, in part, from mitochondrial dysfunction in neuronal cells, leading to impaired energy production and increased oxidative stress. Because riboflavin serves as a precursor to the flavin coenzymes FMN and FAD—both essential for mitochondrial function—supplementation may help stabilize energy production in neurons and reduce migraine frequency and severity.
Multiple studies, including systematic reviews and retrospective cohorts, indicate that riboflavin supplementation can reduce migraine frequency, number of migraine days, and use of analgesics in children and adolescents, with a favorable safety profile and minimal side effects reported. Doses studied range from low-dose (10–40 mg/day) to higher doses (200–400 mg/day), with both regimens showing benefit, but higher doses showing a more consistent response. Optimal dosing and duration remain to be clarified.
Riboflavin is typically well tolerated in children, with few reported side effects apart from benign flavinuria. Some providers prefer to use activated riboflavin-5’-phosphate for potentially better absorption, although comparative studies in pediatric migraine are lacking. For optimal results, riboflavin should be taken daily for at least 3 months, and may be combined with other mitochondrial support nutrients such as magnesium and CoQ10.
There is evidence supporting the use of riboflavin (vitamin B2) in the treatment and management of certain mitochondrial diseases in pediatric patients, specifically in genetically defined, riboflavin-responsive disorders. The most well-established indication is riboflavin transporter deficiency (RTD, formerly Brown-Vialetto-Van Laere syndrome), see below.
Riboflavin is also effective in multiple acyl-CoA dehydrogenase deficiency (MADD, also known as glutaric aciduria type II), a mitochondrial fatty acid β-oxidation disorder. In late-onset or riboflavin-responsive MADD, supplementation can lead to rapid and dramatic clinical improvement, including reversal of myopathy and metabolic decompensation. Other rare mitochondrial disorders, such as ACAD9 deficiency, FAD synthetase deficiency, and certain cases of complex I deficiency, may also respond to riboflavin, though the evidence is primarily from case reports and small series.
For primary mitochondrial diseases not linked to flavoenzyme or riboflavin transporter defects, the evidence for riboflavin is limited and largely anecdotal.
There is limited but suggestive evidence that riboflavin plays a role in certain skin disorders in children—primarily when deficiency is present. Historically, ariboflavinosis has been linked to seborrheic dermatitis-like eruptions and angular cheilitis in infants and young children, with small case reports from the 20th century showing resolution after riboflavin supplementation Clinical guidelines acknowledge riboflavin deficiency as a predisposing factor, although large-scale, controlled trials in pediatric populations are lacking .
Recent epidemiological data in adults reveal an inverse association between dietary riboflavin intake and psoriasis risk, suggesting a potential anti-inflammatory or antioxidant role for the vitamin. While this supports mechanistic plausibility, pediatric studies are absent. Additionally, preclinical research in murine models shows that riboflavin (and its metabolite FMN) can reduce histamine-induced pruritus, acting via TRPV1 pathways —though this has not yet translated into clinical research or pediatric trials.
Riboflavin transporter deficiency (RTD), formerly known as Brown-Vialetto-Van Laere syndrome (BVVL), is a rare but severe neurodegenerative disorder caused by mutations in the SLC52A2 or SLC52A3 genes, which encode riboflavin transporters RFVT2 and RFVT3, respectively. These transporters are essential for the cellular uptake of riboflavin and the maintenance of flavin homeostasis. Without adequate transporter function, riboflavin cannot be efficiently absorbed from the intestine or transported into target tissues, resulting in intracellular riboflavin deficiency—even in the presence of normal dietary intake.
Clinically, RTD typically presents in childhood or adolescence with progressive cranial nerve dysfunction, sensorineural deafness, bulbar palsy, muscle weakness, respiratory compromise, and ataxia. Riboflavin transporter deficiency is often misdiagnosed as other neuromuscular disorders, including spinal muscular atrophy or mitochondrial disease. Key diagnostic clues include early-onset sensorineural hearing loss, brainstem dysfunction, and response to riboflavin supplementation. Genetic testing remains the gold standard for diagnosis, while plasma acylcarnitine profiles and urine organic acid panels may reveal secondary biochemical signatures of multiple acyl-CoA dehydrogenase deficiency (MADD), a riboflavin-responsive disorder with overlapping features.
Some patients exhibit rapid neurologic decline if untreated. Because FAD and FMN are essential cofactors in mitochondrial electron transport and fatty acid oxidation, RTD results in widespread metabolic dysfunction. Early diagnosis is critical, as high-dose riboflavin therapy can dramatically slow or even halt disease progression in many cases. Doses typically range from 10–50 mg/kg/day in divided doses and are generally well tolerated.
Although definitive clinical trials are limited, emerging studies suggest a potential role for riboflavin in supporting metabolic function in children with autism spectrum disorder (ASD). In a 2011 intervention involving 30 children with ASD, daily supplementation of 20 mg riboflavin combined with 500 mg vitamin B6 and 200 mg magnesium over three months led to a significant reduction in urinary dicarboxylic acids—metabolic markers of mitochondrial dysfunction—from pathological to near-normal levels. While this suggests improved fatty acid oxidation and energy metabolism, the effect cannot be separated from the contributions of B6 and magnesium.
Supporting this, a large observational study of 600 children with ASD identified functional riboflavin deficiency—i.e., impaired conversion to FMN and FAD—using urine organic acid testing. Many cases correlated with elevated markers of impaired mitochondrial enzyme activity. These findings indicate a bioenergetic deficit in ASD that could plausibly respond to targeted riboflavin repletion, though interventional evidence remains preliminary.
In summary, current data indicate biochemical abnormalities consistent with riboflavin insufficiency in ASD and suggest potential benefits when used alongside cofactors. However, rigorously controlled pediatric trials isolating riboflavin supplementation are lacking. At present, it may be considered as part of a broader mitochondrial-supportive nutrient regimen in select cases, with the understanding that evidence is early-stage.
Sherwood M, Goldman RD. Effectiveness of riboflavin in pediatric migraine prevention. Can Fam Physician. 2014 Mar;60(3):244-6. PMID: 24627379; PMCID: PMC3952759.
Gregory Russell-Jones. Functional Vitamin B2 Deficiency in Autism. Journal of Pediatrics, Perinatology and Child Health 6 (2022): 324-328.
Kałużna-Czaplińska J, Socha E, Rynkowski J. B vitamin supplementation reduces excretion of urinary dicarboxylic acids in autistic children. Nutr Res. 2011 Jul;31(7):497-502. doi: 10.1016/j.nutres.2011.06.002. PMID: 21840465.
Mahabadi N, Bhusal A, Banks SW. Riboflavin Deficiency. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470460/
Condò M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009 Oct;10(5):361-5. doi: 10.1007/s10194-009-0142-2. Epub 2009 Aug 1. PMID: 19649688; PMCID: PMC3452096.
Li A, Chen F, Xia Q, Liu B, Xu J, Song X, Xu T, Cui Y. Riboflavin Deficiency Associated With Psoriasis: Insights From Population and Transcriptome. Exp Dermatol. 2025 May;34(5):e70106. doi: 10.1111/exd.70106. PMID: 40312926.
Martello E, Aiyelabegan F, Orr J, Wilson E, Morling JR, Kinali M, Joseph T, Koboto D, Dhungana S, Ikechukwu P, Seripenah P, Emery H, Stewart-Evans J, Leonardi-Bee J. Systematic Review Suggests Nutraceuticals Containing Vitamin B2 Could Provide an Alternative Treatment for Paediatric Migraines. Acta Paediatr. 2025 Oct;114(10):2443-2457. doi: 10.1111/apa.70157. Epub 2025 May 24. PMID: 40411246; PMCID: PMC12420874.
Suwannasom N, Kao I, Pruß A, Georgieva R, Bäumler H. Riboflavin: The Health Benefits of a Forgotten Natural Vitamin. Int J Mol Sci. 2020 Jan 31;21(3):950. doi: 10.3390/ijms21030950. PMID: 32023913; PMCID: PMC7037471.
